PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNoticescategoryCategories
BuyersSuppliersNoticesCategories
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Cipla (EU) Limited
C(

Cipla (EU) Limited

Addlestone
Large
cipla.co.uk ↗
Compare peers
Awarded
£1.2bn
Live
16
Buyers
5
12m
£1.2bn
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts16 / 26
  • Top buyers5
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Cipla (EU) LimitedUpdated 13 Jul 2026

At a glance · for buyers and watchdogs

Cipla (EU) Limited has won £1.2bn across 5 public-sector buyers, with 16 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
16 of 26Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

⚑ Self-reported & from notices

Service tags, sectors served and target geographies appear here once a supplier verifies ownership of this profile.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 16 live · 10 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
NHS England—01 Sept 2026£166.3m2 yrspending
NHS National Generics Pharmaceuticals - Supply Chain Resilience
NHS England—01 Sept 2026£35.0m1.8 yrspending
NHS National Branded Interim - 1 June 2026
NHS England—01 Jun 2026£529.1m1.9 yrspending
NHS National Generic Pharmaceuticals - Wave 15c
NHS England—01 Jun 2026£403.7m2 yrspending
NHS National Framework for Generics Housekeeping
NHS England—01 Feb 2026£21.6m1.7 yrspending
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024
NHS England3360000001 May 2024£11.2m4 yrsLive
NHS National Pharmaceuticals Transition 2021_3
NHS England3360000001 Oct 2021£722k2.7 yrsClosed
NHS National Generic Pharmaceuticals - Transition 2021_2
NHS England3360000015 Jun 2021£163k1.7 yrsClosed
NHS National Pharmaceuticals - Fulvestrant, Darunavir and Imatinib
NHS England3360000015 Jan 2021£1.7m9 moClosed
NHS National Generic Pharmaceuticals Interim 2
NHS England3369000001 Feb 2021£242k13 moClosed
Total live value £11.2m · mean award £45.7m1–10 of 26

Top buyers · 5 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
17 contracts
100%
since 2019
2
The NHS Commissioning Board (operating under the name of NHS England)
5 contracts
0%
3
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
2 contracts
0%
4
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
1 contract
0%
5
eTenderwales
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire17 contracts
100%
North West5 contracts
0%
Scotland2 contracts
0%
Wales2 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Cipla (EU) Limited highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
C(
Cipla (EU) Limited
No£1.2bn—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Mar 2025
Confirmation statement
Up to date
Next due 30 Aug 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
04513292
Status
Active
Type
Private limited
Incorporated
16 Aug 2002
Reg. office
Dixcart House Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE
SIC codes
46460 · 82990
Last accounts
31 Mar 2025
Next accounts due
31 Dec 2026

Directors & PSC

  • KILIROORCHERAYIL, Jortin George — director
    Appointed 09 Dec 2024
  • ADUKIA, Ashish — director
    Appointed 07 Jun 2024
  • MALPANI, Swapn — director
    Appointed 28 Mar 2024
  • HOCINE, Sahid, Dr — director
    Appointed 30 Aug 2022

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
CIPLA (EU) LIMITED
04513292 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.